Patent & Trade Mark
Attorneys
 

WEBINAR: Investor Briefing with Monsoon Communications

Date: 16 June 2020
SHARE
 
 

On Tuesday 23 June,  join us for a briefing by Zelira Therapeutics MD Richard Hopkins and Rhinomed MD & CEO Michael Johnson, hosted by David Blake, publisher of Bioshares.

Monsoon Communications briefings are aimed towards investors, but this webinar registration is open to anyone who is interested.

 

 


 

Webinar Details

WHEN: 11:00am to 11:40am AEST, Tuesday 23 June 2020

WHERE: Zoom - link provided upon registration

PRESENTERS: Richard Hopkins and Michael Johnson

HOST: David Blake

 


 

Zelira Therapeutics (ASX: ZLD)

  • World first trial assessing the impact of cannabis on sleep successfully met clinical endpoints
  • TasAlk to manufacture Zelira's Insomnia and HOPE™ products, set to launch in Australia in Q3 2020
  • Discussions to license Zelira products in the US and distribute clinically validated products in countries such as UK and Germany
  • Recruitment and dosing completed for Opioid reduction study, final report likely released Q2 2020
  • Recruitment completed for Autism observational study, collaboration with The Parkinson's Foundation progressing
  • Closed FY20 Q3 with a cash position of $4.02 million

Market cap ~ $58m

 

 

 

 

Rhinomed Limited (ASX: RNO)

  • Next generation of nasal technology, Pronto Sleep and Pronto Clear, successfully released
  • Continued rapid growth from targeting large addressable markets in sport, sleep, respiration, allergies, congestion & anxiety
  • Record quarterly revenue of $1.296 million in FY20 Q3
  • FY20 Q3 cash receipts up 38% year on year 
  • Significant growth in store numbers expected throughout 2020
    • Pronto to appear in 6,336 new US stores from September 2020
    • Projected expansion into 30,000 stores globally by 2021

Market cap ~$14m


 

Please direct any questions to Rudi Michelson, Founder of Monsoon Communications, at rudim@monsoon.com.au

 

Tags:  Investor, Opthea, Pharmaxis

Subscribe via Email